Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1253-1258

  Lewis, Russell E ^a,b   Liao, Guangling ^a   Hou, Jinggou ^a   Chamilos, Georgios ^b   Prince, Randall A ^a,b   Kontoyiannis, Dimitrios P ^a,b  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CORTISONE; CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLUS FUMIGATUS; BAGG ALBINO MOUSE; CONIDIUM; CONTROLLED STUDY; DISEASE MODEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; LUNG ASPERGILLOSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SINGLE DRUG DOSE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; DISEASE MODELS, ANIMAL; LIPIDS; LIPOSOMES; LUNG DISEASES, FUNGAL; MICE; MICE, INBRED BALB C;

EID: 34247146273     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01449-06     Document Type: Article

References (31)

1. Adedoyin, A., C. E. Swenson, L. E. Bolcsak, A. Hellmann, D. Radowska, G. Horwith, A. S. Janoff, and R. A. Branch. 2000. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob. Agents Chemother. 44:2900-2902.
2. Aisner, J., P. H. Wiernik, and S. C. Schimpff. 1977. Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response. Ann. Intern. Med. 86:539-543.
3. Andes, D., N. Safdar, K. Marchillo, and R. Conklin. 2006. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models. Antimicrob. Agents Chemother. 50:674-684.
4. Balloy, V., M. Huerre, J. P. Latge, and M. Chignard. 2005. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect. Immun. 73:494-503.
5. Barnes, P. D., and K. A. Marr. 2006. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect. Dis. Clin. N. Am. 20:545-561, vi.
6. Becker, M. J., S. de Marie, M. H. Fens, W. C. Hop, H. A. Verbrugh, and I. A. Bakker-Woudenberg. 2002. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungi-zone as assessed by several parameters of antifungal response. J. Antimicrob. Chemother. 49:813-820.
7. Bekersky, I., R. M. Fielding, D. E. Dressier, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833.
8. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:834-840.
9. Bowman, J. C., G. K. Abruzzo, J. W. Anderson, A. M. Flattery, C. J. Gill, V. B. Pikounis, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.
10. Clemons, K. V., and D. A. Stevens. 2004. Comparative efficacies of four amphotericin B formulations-Fungizone, amphotec (Amphocil), AmBisome, and Abelcet-against systemic murine aspergillosis. Antimicrob. Agents Chemother. 48:1047-1050.
11. Denning, D. W. 1996. Therapeutic outcome in invasive aspergillosis. Clin. Infect. Dis. 23:608-615.
12. Groll, A. H., D. Mickiene, V. Petraitis, R. Petraitiene, R. M. Alfaro, C. King, S. C. Piscitelli, and T. J. Walsh. 2003. Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits. Antimicrob. Agents Chemother. 47:3917-3925.
13. Groll, A. H., D. Mickiene, K. Werner, R. Petraitiene, V. Petraitis, M. Calendario, A. Field-Ridley, J. Crisp, S. C. Piscitelli, and T. J. Walsh. 2000. Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits. Antimicrob. Agents Chemother. 44:950-957.
14. Janknegt, R., S. de Marie, I. A. Bakker-Woudenberg, and D. J. Crommelin. 1992. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin. Pharmacokinet. 23:279-291.
15. Lewis, R. E., R. A. Prince, J. Chi, and D. P. Kontoyiannis. 2002. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 46:3208-3214.
16. Lewis, R. E., and N. P. Wiederhold. 2005. Murine model of invasive aspergillosis. Methods Mol. Med. 118:129-142.
17. Lewis, R. E., N. P. Wiederhold, and M. E. Klepser. 2005. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob. Agents Chemother. 49:945-951.
18. Linden, P. K. 2003. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin. Pharmacother. 4:2099-2110.
19. Matot, I., and R. Pizov. 2000. Pulmonary extraction and accumulation of lipid formulations of amphotericin B. Crit. Care Med. 28:2528-2532.
20. Ng, T. K., R. C. Chan, F. A. Adeyemi-Doro, S. W. Cheung, and A. F. Cheng. 1996. Rapid high performance liquid chromatographic assay for antifungal agents in human sera. J. Antimicrob. Chemother. 37:465-472.
21. Nierman, W. C., A. Pain, M. J. Anderson, J. R. Wortman, H. S. Kim, J. Arroyo, M. Berriman, K. Abe, D. B. Archer, C. Bermejo, J. Bennett, P. Bowyer, D. Chen, M. Collins, R. Coulsen, R. Davies, P. S. Dyer, M. Farman, N. Fedorova, N. Fedorova, T. V. Feldblyum, R. Fischer, N. Fosker, A. Fraser, J. L. Garcia, M. J. Garcia, A. Goble, G. H. Goldman, K. Gomi, S. Griffith-Jones, R. Gwilliam, B. Haas, H. Haas, D. Harris, H. Horiuchi, J. Huang, S. Humphray, J. Jimenez, N. Keller, H. Khouri, K. Kitamoto, T. Kobayashi, S. Konzack, R. Kulkarni, T. Kumagai, A. Lafon, J. P. Latge, W. Li, A. Lord, C. Lu, W. H. Majoros, G. S. May, B. L. Miller, Y. Mohamoud, M. Molina, M. Monod, I. Mouyna, S. Mulligan, L. Murphy, S. O'Neil, I. Paulsen, M. A. Penalva, M. Pertea, C. Price, B. L. Pritchard, M. A. Quail, E. Rabbinowitsch, N. Rawlins, M. A. Rajandream, U. Reichard, H. Renauld, G. D. Robson, S. Rodriguez de Cordoba, J. M. Rodriguez-Pena, C. M. Ronning, S. Rutter, S. L. Salzberg, M. Sanchez, J. C. Sanchez-Ferrero, D. Saunders, K. Seeger, R. Squares, S. Squares, M. Takeuchi, F. Tekaia, G. Turner, C. R. Vazquez de Aldana, J. Weidman, O. White, J. Woodward, J. H. Yu, C. Fraser, J. E. Galagan, K. Asai, M. Machida, N. Hall, B. Barrel I, and D. W. Denning. 2005. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 438:1151-1156.
22. Olson, J. A., J. P. Adler-Moore, J. Schwartz, G. M. Jensen, and R. T. Proffitt. 2006. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Antimicrob. Agents Chemother. 50:2122-2131.
23. Ostrosky-Zeichner, L., B. D. Alexander, D. H. Kett, J. Vazquez, P. G. Pappas, F. Saeki, P. A. Ketchum, J. Wingard, R. Schiff, H. Tamura, M. A. Finkelman, and J. H. Rex. 2005. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41:654-659.
24. Pfaller, M. A., D. J. Sheehan, and J. H. Rex. 2004. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17:268-280.
25. Proffitt, R. T., A. Satorius, S. M. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B):49-61.
26. Segarra, I., D. A. Movshin, and L. Zarif. 2002. Pharmacokinetics and tissue distribution after intravenous administration of a single dose of amphotericin B cochleates, a new lipid-based delivery system. J. Pharm. Sci. 91:1827-1837.
27. Shibuya, K., M. Takaoka, K. Uchida, M. Wakayama, H. Yamaguchi, K. Takahashi, S. Paris, J. P. Latge, and S. Naoe. 1999. Histopathology of experimental invasive pulmonary aspergillosis in rats: pathological comparison of pulmonary lesions induced by specific virulent factor deficient mutants. Microb. Pathog. 27:123-131.
28. Tamura, H., Y. Arimoto, S. Tanaka, M. Yoshida, T. Obayashi, and T. Kawai. 1994. Automated kinetic assay for endotoxin and (1→3)-beta-D- glucan in human blood. Clin. Chim. Acta 226:109-112.
29. Walsh, T. J., J. L. Goodman, P. Pappas, I. Bekersky, D. N. Buell, M. Roden, J. Barrett, and E. J. Anaissie. 2001. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. 45:3487-3496.
30. Wiederhold, N. P., D. P. Kontoyiannis, J. Chi, R. A. Prince, V. H. Tam, and R. E. Lewis. 2004. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J. Infect. Dis. 190:1464-1471.
31. Wiederhold, N. P., V. H. Tam, J. Chi, R. A. Prince, D. P. Kontoyiannis, and R. E. Lewis. 2006. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 50:469-473.